Strata Skin Sciences Files Form 25, Plans Form 15 to Delist from Nasdaq
Strata Skin Sciences filed Form 25 to delist from Nasdaq on February 19 and will file Form 15 on March 2 to terminate SEC registration. The company ended fiscal 2025 with $8 million cash and anticipates cutting compliance costs to reduce burn and fund XTRAC and TheraclearX market expansion.
1. Nasdaq Delisting and Registration Termination
Strata Skin Sciences filed a Form 25 with the SEC to deregister its common stock under Section 12(b) of the Exchange Act, resulting in the suspension of trading on the Nasdaq Capital Market effective February 19. The company plans to file a Form 15 around March 2 to terminate its Section 12(g) registration and suspend reporting obligations.
2. Cost Savings and Operational Focus
Management expects the delisting and “going dark” process to eliminate burdensome listing requirements and reduce general and administrative expenses. The company anticipates these savings will lower cash burn and enable reinvestment in core business operations.
3. Financial Position and Lender Negotiations
Strata ended fiscal 2025 with a cash balance of $8 million and reports no financial instability underlying the decision to delist. The board is negotiating with its lender to adjust loan terms reflecting its status as a private company.
4. Market Expansion and Long-Term Outlook
Leadership highlights anticipated market expansion for its XTRAC excimer laser and TheraclearX products following recent CPT code changes. With a streamlined cost profile, the company aims to focus management on long-term value creation and operational growth.